Corza Health has signed an agreement to acquire Takeda Pharmaceutical’s TachoSil Fibrin Sealant Patch for about $414.3 million (€350 million).

TachoSil is a surgical patch that controls bleeding. The patch brought in about $160 million for Takeda in its fiscal year that ended March 31st. Upon close, Corza Health said it will acquire the assets and licenses that support the development and commercialization of TachoSil, while Takeda maintains ownership of the manufacturing facility in Linz, Austria.

Takeda has entered into a long-term manufacturing services agreement, under which it will continue to manufacture TachoSil products and supply them to Corza Health.

“This announcement continues Takeda’s strong momentum toward optimizing our portfolio for growth by delivering highly-innovative medicines and transformative care in our chosen business areas, as well as meeting our leverage targets,” said Costa Saroukos, CFO, Takeda, in prepared remarks.  As we continue to streamline and simplify our portfolio, Takeda is confident that we have found the right partner in Corza Health as the next home for TachoSil.”

Previously Johnson & Johnson’s Ethicon was set to acquire TachoSil for about $400 million. However, both J&J and Takeda walked away from the deal because of anti-trust concerns in April of this year.  

Corza Health, however, doesn’t have an extensive portfolio like J&J and shouldn’t run into any anti-trust concerns. The company is relatively new, having been formed in 2019 as a partnership between private equity firm GTCR and healthcare industry veteran Gregory Lucier.